Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > REGULATORY
REGULATORY
- Spinraza’s 9.32 Million Yen Price Tag OK’ed for Listing on Aug. 30
August 23, 2017
- Final Report on MID-NET’s Full Operations Published
August 22, 2017
- MHLW Study Group to Expand Investigation to Clinics to Determine Causes of Improper Promotional Activities
August 22, 2017
- Clinical Research Law to Apply to Indirectly Funded Programs Too, MHLW to Clarify Procedures: Official
August 21, 2017
- MHLW Advisory Panel to Review Budesonide Rectal Foam on Sept. 1
August 21, 2017
- 11 Firms Get Approval for Irbesartan Generics towards December Listing, including AG; 26 Flock to Crestor
August 16, 2017
- NIBIOHN to Promote Drug Discovery in Fields with Unmet Needs by Automating Target Discovery Using AI
August 15, 2017
- “Pediatric Treatment” Excluded from Appraisal Adjustment Factors in Pilot Program: Chuikyo
August 10, 2017
- MHLW Wants to Use Past Surveys, Overseas Examples for ICER Yardstick in CEA Pilot Program, Plan Draws Fire from Payers Reps: Chuikyo
August 10, 2017
- Calls Growing for Tougher Requirements to Receive Price Maintenance Premium: Chuikyo
August 10, 2017
- New Measures Needed to Ramp Up Generic Use: Chuikyo
August 10, 2017
- MHLW Orders Label Revisions for Warfarin, 3 Other APIs
August 7, 2017
- (Update) Katsunobu Kato Tapped as New Health Minister
August 4, 2017
- Clinical Research Law to Apply to “Nearly All Drug-Related Clinical Research” Funded by Drug Makers: MHLW
August 4, 2017
- Katsunobu Kato Tapped as New Health Minister
August 3, 2017
- “We Should Increase Our Efforts” to Promote Pharmaceutical Industry: New Health Policy Bureau Chief Takeda
August 3, 2017
- MHLW Advisory Panel Recommends Approval for Zetia/Lipitor Combo
August 3, 2017
- Bayer’s ADR Reporting Delay “Very Regrettable”: Shiozaki
August 2, 2017
- Will “Emphasize Exchange of Views” to Tackle Challenges: Pharma Bureau Chief Miyamoto
August 1, 2017
- MHLW to Support Healthcare-Related Startups from “Long-Term Perspective”: Health Minister Shiozaki
August 1, 2017
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…